<?xml version="1.0" encoding="UTF-8"?>
<p>Venetoclax monotherapy preserves T-cells, and immunoglobulins, while transiently reducing the B-lymphocyte count. B-lymphocytes recover to normal levels within an average of 60 days from venetoclax discontinuation.
 <sup>
  <xref rid="R83" ref-type="bibr">83</xref>,
  <xref rid="R91" ref-type="bibr">91</xref>
 </sup> The disadvantage of venetoclax treatment is the need for frequent access to the hospital during the ramp-up phase to prevent tumor lysis syndrome (TLS).
 <sup>
  <xref rid="R58" ref-type="bibr">58</xref>
 </sup> In addition, venetoclax treatment has a relatively high risk of neutropenia during the first 3 months, though it does not translate into a high rate of infections and can be easily prevented through the use of G-CSF.
 <sup>
  <xref rid="R79" ref-type="bibr">79</xref>
 </sup> There is no evidence to support if, and to what extent, neutropenia is predictive of a negative outcome in SARS-CoV-2 infection.
</p>
